Did you know? You can suggest edits to improve this peptide information.
Overview
What is Thymosin Beta-4?
Thymosin Beta-4 (Tβ4) is a naturally occurring 43-amino acid peptide that plays a crucial role in tissue repair, wound healing, and cellular regeneration. It promotes angiogenesis, reduces inflammation, and supports the migration and differentiation of various cell types involved in healing processes.
Key Benefits
Systemic regenerative effects, proven clinical efficacy, optimal bioavailability for tissue repair
Mechanism of Action
Direct systemic delivery provides optimal bioavailability and distribution to target tissues for comprehensive regenerative effects
Molecular Information
Weight
4,963.44 Da
Length
43 amino acids
Type
Thymosin peptide
Amino Acid Sequence:
Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser
* N-terminal acetylation, naturally occurring in thymus
Research Indications
Wound Healing Acceleration
Clinical trials show 67% complete healing vs 25% placebo in pressure ulcers
Post-Surgical Recovery
Enhanced tissue regeneration and reduced healing time in surgical wounds
Soft Tissue Injury Repair
Accelerated recovery in muscle, tendon, and ligament injuries
Research Protocols
Disclaimer
These are commonly discussed research protocols and not medical advice. Consult a healthcare provider before use.
Timing
Most effective when started early in the injury/healing process. For cardiac protection, must be given within 6 hours of symptom onset. Can be administered any time of day for chronic conditions.
Peptide Interactions
How to Reconstitute
Important
Always use bacteriostatic water (BAC). Sterile technique is essential.
Allow lyophilized powder to reach room temperature before reconstitution
Add bacteriostatic water slowly to the vial wall, avoiding direct contact with powder
Gently swirl (do not shake vigorously) until completely dissolved
Inspect solution for clarity - should be clear and colorless
Store reconstituted solution at 2-8°C and use within 14 days
For injection, use proper aseptic technique and rotate injection sites
Quality Indicators
Clear, colorless solution
Reconstituted Thymosin β4 should be clear and colorless without particles
Proper sterile packaging
Lyophilized powder in sterile vials with intact seals and labeling
Certificate of analysis
Third-party testing showing >98% purity and endotoxin levels <10 EU/mg
Appropriate molecular weight
HPLC/MS confirmation of 4,921 Da molecular weight for 43-amino acid sequence
Cloudy or discolored solution
Any turbidity or color change indicates degradation or contamination
Crystallization after reconstitution
Visible crystals suggest improper storage or expired product
Room temperature storage claims
Legitimate Thymosin β4 requires refrigeration after reconstitution
What to Expect
- Week 1-2: Initial tissue response, possible mild injection site reactions
- Week 2-4: Accelerated healing becomes apparent, reduced inflammation
- Week 4-8: Significant tissue regeneration and functional improvement
- Week 8-12: Sustained benefits and near-complete healing in responsive conditions
Side Effects & Safety
- Monitor injection sites for local reactions or inflammation
- Use sterile technique to prevent infection at injection sites
- Start with lower doses to assess individual tolerance
- Discontinue if signs of allergic reaction or unusual side effects
References
Cardiac Protection Pilot Study: Thymosin β4 in STEMI Patients (2016)
First human study of Thymosin β4 in heart attack patients, demonstrating potential clinical benefits in repairing damaged tissue and improving cardiac function.
View Study (opens in new tab) →Phase II Dry Eye Clinical Trial Using Controlled Adverse Environment Model (2015)
Randomized, double-masked, placebo-controlled study in 72 subjects showing significant positive effects on ocular discomfort and corneal staining with excellent safety profile.
View Study (opens in new tab) →Phase I Human Safety Study: Intravenous Thymosin β4 (2010)
First-in-human randomized, placebo-controlled study establishing safety and pharmacokinetics of IV Thymosin β4 administration in healthy volunteers.
View Study (opens in new tab) →Quick Start Guide
Community Poll
Question 1 of 10
What is your experience with this compound?
Poll Results
Loading results...
Community Insights
Self-reported by Nootpedia users. Not clinical evidence. Health changes reflect all users, including those taking multiple compounds.
Was this helpful?
Your feedback helps us improve Nootpedia